S.A. Mason LLC Has $2.27 Million Stock Holdings in AbbVie Inc. (NYSE:ABBV)

S.A. Mason LLC lifted its holdings in shares of AbbVie Inc. (NYSE:ABBV) by 0.8% during the 4th quarter, according to the company in its most recent 13F filing with the Securities & Exchange Commission. The fund owned 12,745 shares of the company’s stock after purchasing an additional 104 shares during the quarter. AbbVie makes up about 1.2% of S.A. Mason LLC’s holdings, making the stock its 14th biggest position. S.A. Mason LLC’s holdings in AbbVie were worth $2,265,000 at the end of the most recent quarter.

A number of other hedge funds and other institutional investors have also modified their holdings of ABBV. Groupama Asset Managment lifted its stake in shares of AbbVie by 40.3% in the third quarter. Groupama Asset Managment now owns 135,749 shares of the company’s stock worth $27,000 after buying an additional 38,974 shares during the last quarter. RPg Family Wealth Advisory LLC bought a new position in AbbVie in the 3rd quarter worth $28,000. Fiduciary Advisors Inc. acquired a new position in AbbVie during the 4th quarter worth $29,000. Retirement Wealth Solutions LLC bought a new stake in AbbVie during the fourth quarter valued at about $35,000. Finally, Marquette Asset Management LLC acquired a new stake in shares of AbbVie in the third quarter valued at about $39,000. Institutional investors own 70.23% of the company’s stock.

AbbVie Stock Up 4.7 %

ABBV stock opened at $183.90 on Monday. AbbVie Inc. has a twelve month low of $153.58 and a twelve month high of $207.32. The company has a market cap of $324.98 billion, a price-to-earnings ratio of 63.85, a P/E/G ratio of 1.77 and a beta of 0.58. The company has a quick ratio of 0.54, a current ratio of 0.65 and a debt-to-equity ratio of 9.64. The business has a 50 day moving average price of $176.57 and a two-hundred day moving average price of $185.06.

AbbVie (NYSE:ABBV) last released its quarterly earnings data on Friday, January 31st. The company reported $2.16 earnings per share for the quarter, missing the consensus estimate of $2.98 by ($0.82). AbbVie had a return on equity of 244.01% and a net margin of 9.22%. During the same quarter last year, the business earned $2.79 EPS. Analysts anticipate that AbbVie Inc. will post 10.09 EPS for the current fiscal year.

Analyst Upgrades and Downgrades

ABBV has been the topic of several research reports. Guggenheim boosted their price target on AbbVie from $212.00 to $221.00 and gave the company a “buy” rating in a research note on Wednesday, November 6th. UBS Group boosted their price objective on AbbVie from $195.00 to $200.00 and gave the company a “neutral” rating in a research report on Thursday, October 31st. Citigroup reduced their target price on AbbVie from $215.00 to $205.00 and set a “buy” rating for the company in a research report on Tuesday, January 28th. Daiwa America lowered shares of AbbVie from a “strong-buy” rating to a “hold” rating in a report on Thursday, December 5th. Finally, Morgan Stanley reduced their price objective on shares of AbbVie from $231.00 to $224.00 and set an “overweight” rating for the company in a report on Tuesday, November 12th. Five research analysts have rated the stock with a hold rating, seventeen have given a buy rating and two have issued a strong buy rating to the company. According to data from MarketBeat, AbbVie presently has an average rating of “Moderate Buy” and a consensus price target of $205.00.

Insider Buying and Selling at AbbVie

In related news, SVP Kevin K. Buckbee sold 1,800 shares of the business’s stock in a transaction that occurred on Monday, December 16th. The stock was sold at an average price of $172.24, for a total value of $310,032.00. Following the completion of the sale, the senior vice president now directly owns 6,983 shares in the company, valued at approximately $1,202,751.92. The trade was a 20.49 % decrease in their ownership of the stock. The sale was disclosed in a filing with the SEC, which is accessible through this link. Insiders own 0.25% of the company’s stock.

AbbVie Profile

AbbVie Inc discovers, develops, manufactures, and sells pharmaceuticals worldwide. The company offers Humira, an injection for autoimmune and intestinal Behçet's diseases, and pyoderma gangrenosum; Skyrizi to treat moderate to severe plaque psoriasis, psoriatic disease, and Crohn's disease; Rinvoq to treat rheumatoid and psoriatic arthritis, ankylosing spondylitis, atopic dermatitis, axial spondyloarthropathy, ulcerative colitis, and Crohn's disease; Imbruvica for the treatment of adult patients with blood cancers; Epkinly to treat lymphoma; Elahere to treat cancer; and Venclexta/Venclyxto to treat blood cancers.